NCT02729298 2023-11-14
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
Phase 1 Completed
Clinical Trials
3 trialsNCT03572634 2023-11-09
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
Sumitomo Pharma America, Inc.
Phase 1/2 Terminated
NCT04518345 2023-02-06
TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed